Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ADHD Drug Cardiac Events, COX-2s Are Topics For Drug Safety Committee Meeting

This article was originally published in The Pink Sheet Daily

Executive Summary

Studies to determine risk of cardiovascular adverse outcomes with attention deficit/hyperactivity disorder drugs will be discussed at Feb. 9-10 meeting. Risk management programs for isotretinoin products also on the agenda.

You may also be interested in...



Cardiac, Neuropsychiatric Events With ADHD Drugs To Be Discussed By Pediatric Committee

FDA's Pediatric Advisory Committee will address neuropsychiatric and cardiovascular events possibly related to attention deficit/hyperactivity disorder medications at a March 22 meeting

Cephalon Sparlon For ADHD To Get Psychopharm Committee Review

The March 23 review of the new indication for modafinil, currently marketed as Provigil for narcolepsy, will likely focus on safety differences compared to other ADHD drugs.

Cardiac, Neuropsychiatric Events With ADHD Drugs To Be Discussed By Pediatric Committee

FDA's Pediatric Advisory Committee will address neuropsychiatric and cardiovascular events possibly related to attention deficit/hyperactivity disorder medications at a March 22 meeting

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS063142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel